These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35286757)

  • 1. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
    Sobh EA; Khalil NA; Faggal SI; Hassan MSA
    Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells.
    Omar AME; AboulWafa OM; Amr ME; El-Shoukrofy MS
    Bioorg Chem; 2021 Apr; 109():104752. PubMed ID: 33657444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
    Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM
    Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
    Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
    Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
    A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
    Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
    AboulWafa OM; Daabees HMG; El-Said AH
    Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Synthesis of Novel Quinazolinone-Based Oxobutanenitrile Derivatives as Antiproliferative Agents Targeting Human Breast Cancer.
    AboulWafa OM; Daabees HMGE; Ezz-ElDien ES
    Anticancer Agents Med Chem; 2022; 22(12):2310-2326. PubMed ID: 34906060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzoxazole derivatives as new generation of anti-breast cancer agents.
    Omar AME; AboulWafa OM; El-Shoukrofy MS; Amr ME
    Bioorg Chem; 2020 Mar; 96():103593. PubMed ID: 32004897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF
    Abou-Zied HA; Beshr EAM; Gomaa HAM; Mostafa YA; Youssif BGM; Hayallah AM; Abdel-Aziz M
    Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200464. PubMed ID: 36526595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
    Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
    Halim PA; Sharkawi SMZ; Labib MB
    Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
    Raghunath Khedkar N; Sindkhedkar M; Joseph A
    Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.